Literature DB >> 25069730

Prostate cancer: Brachyury--a biomarker for progression and prognosis?

Clemens Thoma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25069730     DOI： 10.1038/nrurol.2014.184

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.

Authors:  Filipe Pinto; Nelma Pértega-Gomes; Márcia S Pereira; José R Vizcaíno; Pedro Monteiro; Rui M Henrique; Fátima Baltazar; Raquel P Andrade; Rui M Reis
Journal:  Clin Cancer Res       Date:  2014-07-09       Impact factor: 12.531
  1 in total
  5 in total

1.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

2.  T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines.

Authors:  Su Chen; Jian Jiao; Dongjie Jiang; Zongmiao Wan; Lei Li; Ke Li; Leqin Xu; Zhenhua Zhou; Wei Xu; Jianru Xiao
Journal:  Tumour Biol       Date:  2015-03-06

Review 3.  Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.

Authors:  Mannan Nouri; Ellca Ratther; Nataly Stylianou; Colleen C Nelson; Brett G Hollier; Elizabeth D Williams
Journal:  Front Oncol       Date:  2014-12-23       Impact factor: 6.244

4.  Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.

Authors:  Filipe Pinto; Nelma Pértega-Gomes; José R Vizcaíno; Raquel P Andrade; Flavio M Cárcano; Rui Manuel Reis
Journal:  Oncotarget       Date:  2016-05-17

Review 5.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-14       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.